Drugs / HL237
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04633733 | Aug → Sep 2020 | — | Hanlim Pharm. Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03896594 | Dec 2018 → Jun 2019 | rheumatoid arthritis | Hanlim Pharm. Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03278470 | Jun 2017 → Mar 2018 | rheumatoid arthritis | Hanlim Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04638426 | Sep 2020 → May 2021 | rheumatoid arthritis | Hanlim Pharm. Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HL237 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04633733 ↗ |
| Action | Inhibit | “HL237 is a STAT3 inhibitor” NCT03278470 ↗ |
| Route | Oral | “After Single Oral Dose of HL237” NCT03278470 ↗ |
| Target | STAT3 | “HL237 is a STAT3 inhibitor” NCT03278470 ↗ |